Cyprotex PLC Partnership in the EC funded EU-ToxRisk consortium

TIDMCRX

Cyprotex PLC

13 October 2015

Cyprotex PLC

("Cyprotex" or "the Company")

Partnership in the EC funded EU-ToxRisk consortium

Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces that it will form part of the EU-ToxRisk consortium; a project funded by the European Commission to work on the integration of new concepts for regulatory chemical safety assessment. A total of 39 partners are involved in the consortium ranging from industry, academia, research institutes, contract research organisations and regulatory bodies.

The EU-ToxRisk project will start in January 2016 and run for 6 years. The project is funded by the European Commission through its Horizon 2020 programme for Research and Innovation and has a total value to all partners of EUR30 million over 6 years. The award to Cyprotex is anticipated to be worth approximately EUR1.0 million over the 6 year period. The aim of the project is to develop new cutting-edge human relevant in vitro non-animal methods and in silico computational technologies for the early assessment of potential toxicity in humans. The ultimate goal is to provide the basis of future regulatory chemical safety testing using animal-free approaches for hazard and risk assessment. Cyprotex plays a major role in the delivery of absorption, distribution, metabolism and excretion (ADME) data to the consortium and will also be involved in validation of some of the newly developed toxicity models.

Anthony Baxter PhD, Chief Executive Officer of Cyprotex, comments, 'We are delighted to be part of the EU-ToxRisk consortium. The project is very much in line with the ethos of the Company where we have been developing in vitro and in silico methods for predicting human outcome for over 16 years. Animal testing is notoriously poor at predicting human safety for certain types of toxicity and awareness of the ethical issues associated with animal testing is growing rapidly. Developing more sophisticated human relevant models will help in addressing these issues, as well as improving the speed and efficiently of screening.'

For more information, the official press release issued by the consortium can be found below:

http://www.rns-pdf.londonstockexchange.com/rns/0271C_-2015-10-12.pdf

Alternatively this is available at the following link:

http://science.leidenuniv.nl/index.php/research/projects/eu-toxrisk

For further information:

 
 Cyprotex PLC                         Tel: [phone] 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   [e-mail] 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad and broker to      Tel: [phone] 
  Cyprotex)                            3000 
 Shaun Dobson                         [e-mail] 
  Jen Boorer                           [e-mail] 
                                       www.n1singer.com 
 

Notes to Editors

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1200 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling using PBPK, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAPKBDDOBDDFKD

(END) Dow Jones Newswires

October 13, 2015 02:00 ET (06:00 GMT)